廣告
香港股市 已收市

  • 恒指

    17,675.82
    +391.28 (+2.26%)
     

  • 國指

    6,279.29
    +158.92 (+2.60%)
     

  • 上證綜指

    3,088.64
    +35.74 (+1.17%)
     

  • 滬深300

    3,584.27
    +53.99 (+1.53%)
     

  • 美元

    7.8283
    +0.0005 (+0.01%)
     

  • 人民幣

    0.9251
    +0.0008 (+0.09%)
     

  • 道指

    38,085.80
    -375.12 (-0.98%)
     

  • 標普 500

    5,048.42
    -23.21 (-0.46%)
     

  • 納指

    15,611.76
    -100.99 (-0.64%)
     

  • 日圓

    0.0498
    -0.0002 (-0.42%)
     

  • 歐元

    8.4068
    +0.0086 (+0.10%)
     

  • 英鎊

    9.7960
    +0.0040 (+0.04%)
     

  • 紐約期油

    83.84
    +0.27 (+0.32%)
     

  • 金價

    2,358.90
    +16.40 (+0.70%)
     

  • Bitcoin

    64,409.67
    +253.51 (+0.40%)
     

  • CMC Crypto 200

    1,388.57
    -7.96 (-0.57%)
     

After Denying Earlier, Pfizer & Merck Marginally Cut Prices For COVID-19 Treatments In China

Vandana Singh
·1 分鐘文章

  • Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) have reportedly lowered the prices of their respective COVID-19 treatments in China.

  • Pfizer cut the price of Paxlovid by about 100 yuan ($14.54) to 1,790 yuan per box of 30 pills, while Merck marginally lowered the price of a 40-capsule bottle of its oral treatment molnupiravir by 74 yuan to 1,426 yuan, Reuters reported citing the financial news outlet, Yicai.

  • Earlier this year, the companies had not agreed to a request by the Chinese authorities for deeper price cuts for COVID-19 treatments.

  • The marginal decline in prices follows China adjusted medical insurance coverage policy for COVID-19 treatments following the abrupt lifting of its zero-COVID policy in early December.

  • Previously, under a temporary policy China enacted for COVID-19 treatments, insured patients only needed to pay 10% of the price for Paxlovid and Merck.

  • That policy expired on March 31, meaning they must now pay full price.

  • In January, Pfizer CEO Albert Bourla rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid.

  • Price Action: MRK stock is up 0.27% at $109.16, and PFE shares are up 0.24% at $41.45 during the premarket session on the last check Tuesday.

  • Photo via Company

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article After Denying Earlier, Pfizer & Merck Marginally Cut Prices For COVID-19 Treatments In China originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.